ArticleJACC. Case reports2025
Ultra-High Density Mapping of Ventricular Tachycardia in a Patient With Arrhythmogenic Right Ventricular Cardiomyopathy: How to Precisely "Pinpoint the Culprit".
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy that often leads to ventricular dysfunction and recurrent ventricular tachycardia (VT). Catheter ablation is a beneficial treatment for ARVC-related VT, but extensive substrate ablation may increase the risk of iatrogenic hemodynamic decompensation. CASE SUMMARY: We describe a 54-year-old female ARVC patient with paroxysmal palpitations and frequent implantable cardioverter-defibrillator discharges. DISCUSSION: This case demonstrates that ultra-high density mapping-guided precise ablation can effectively target the "culprit" substrate in ARVC patients with extensive ventricular scarring, achieving a favorable balance between long-term freedom from VT and preservation of residual cardiac function. TAKE-HOME MESSAGES: Precise ablation balances efficacy and safety by ensuring long-term VT freedom and preserving residual cardiac function in ARVC patients. Comprehensive mapping techniques, including activation mapping, entrainment mapping, and isochronal late activation mapping, improve ablation accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.